GrifolsMEX:GRFP N 83 FCF Margin % is 1.18% as of Mar. 2026, which is 83% below its 10-year median of 6.89. GuruFocus rates MEX:GRFP N with a GF Score™ of 83/100 and a GF Value™ of MXN154.24. The stock has 6 warning signs investors should review. Among 958 Drug Manufacturers companies, Grifols ranks better than 65.34% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Grifols's Free Cash Flow for the
three
months ended in Mar. 2026 was MXN417 Mil. Grifols's Revenue for the
three
months ended in Mar. 2026 was MXN35,440 Mil. Therefore, Grifols's FCF Margin % for the quarter that ended in Mar. 2026 was 1.18%.
The historical rank and industry rank for Grifols's FCF Margin % or its related term are showing as below:
MEX:GRFP N'
s FCF Margin % Range Over the Past 10 Years
Min: -6.5 Med: 6.89 Max: 14
Current: 8.04
During the past 13 years, the highest FCF Margin % of Grifols was 14.00%. The lowest was -6.50%. And the median was 6.89%.
MEX:GRFP N's FCF Margin % is ranked better than 65.34% of 958
companies
in the Drug Manufacturers industry
Industry Median: 2.51
vs MEX:GRFP N: 8.04
Grifols FCF Margin % Related Terms
Grifols FCF Margin % Historical Data
* Premium members only.
The historical data trend for Grifols's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:GRFP N vs LLY, JNJ, ABBV: FCF Margin % Comparison
For the Drug Manufacturers - General subindustry, Grifols's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grifols FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Grifols's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Grifols's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Grifols (MEX:GRFP N) has a FCF Margin % of 1.18% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Grifols and its competitors. This is 83% below median its historical median of 6.89. According to the industry distribution chart, Grifols ranks #332 out of 958 companies in the Drug Manufacturers industry, placing it in the top 34.7%.
Is Grifols' FCF Margin % too high?
Grifols' current FCF Margin % of 1.18% is 83% below median its 10-year median of 6.89. The Drug Manufacturers industry median FCF Margin % is 2.51. Grifols' value of 1.18% is 53% below this industry median. Based on the distribution chart, Grifols ranks #332 out of 958 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Grifols has a GF Score™ of 83/100, reflecting its overall financial health beyond just this single metric.
How does Grifols' FCF Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Grifols ranks #332 out of 958 companies for FCF Margin %. This puts Grifols in the upper half of its industry. The industry median FCF Margin % is 2.51. Grifols' value of 1.18% is 53% below this benchmark. While the company's 10-year median is 6.89 vs. the industry median of 2.51, Grifols has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.51, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grifols's current FCF Margin % of 1.18% is 53% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Grifols and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grifols's current FCF Margin % is 1.18%, which is 83% below median its own 10-year median of 6.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grifols stock overvalued right now?
Grifols (MEX:GRFP N) has a current FCF Margin % of 1.18%. The stock's GF Value™ is MXN154.24, compared to a current price of MXN126.63 — trading 17.9% below its estimated fair value. The current FCF Margin % is 1.18%, which is 83% below median its 10-year median of 6.89 and 53% below the Drug Manufacturers industry median of 2.51. Grifols' overall GF Score™ is 83/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Grifols (MEX:GRFP N), the current FCF Margin % is 1.18% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Grifols (MEX:GRFP N) Overvalued in 2026?
Based on GuruFocus' analysis, Grifols stock appears to be undervalued.
The current stock price of MXN126.63 is trading 17.9% below its estimated GF Value™ of MXN154.24.
Key valuation signals for MEX:GRFP N:
FCF Margin %: 1.18% (83% below median its 10-year median of 6.89)
GF Value™: MXN154.24 vs. price of MXN126.63 (17.9% below fair value)
Industry Position: 53% below the Drug Manufacturers median (#332 of 958)
No single metric tells the full story. See the MEX:GRFP N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.
83GF Score
Get the complete analysis for MEX:GRFP N
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:GRFP N has been successfully added to your 
